Register Login

Thrombophilia

Caplacizumab Immune-mediated TTP Clinical Efficacy Report

Thanks to colleague X. Long Zheng, MD, for his LinkedIn heads-up announcing the 31 March 2025 eClinicalMedicine release of Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project). This pivotal open-access article compares patient mortality rate and the response rate to caplacizumab (Cablivi®) to standard care.
read more

A Molecular Approach to Assess Platelet Hyperreactivity

Friend Ed Groenendal forwarded this UPI summary of a molecular approach correlating evidence of hyperresponsive platelets to major adverse cardiac or limb events. The investigators started with aggregometry-defined platelet hyperreactivity to apply a transcriptome-based platelet reactivity expression score (PRESS). Click below to see the detailed open-access article describing the development and application of the PRESS. […]
read more